AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03575468 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quitline treatment as usual
Description: The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
Study NCT01123304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb028
Description: 1 mg MORAb-028 will be injected at either 1 mg/cm3 per day over 5 days for a total dose of 5 mg for the first cohort and 2 mg/cm3 for the second cohort. Subjects will receive MORAb-028 injections on Days: 1-5, 8-12 and 22-26.
Study NCT04583865 — intervention group
Intervention type: OTHER
Intervention: teleconsultation
Description: In the pandemic period linked to COVID, pediatric pre-anesthesis consultations should preferably be carried out by teleconsultation. This is to assess the effectiveness of these teleconsultation and the satisfaction of parents.
Study NCT00547937 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal continuous positive airway pressure (CPAP) therapy
Description: Nocturnal ventilation through a nasal mask to avoid sleep apneas
Study NCT00547937 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: nasal continuous positive airway pressure (CPAP) therapy
Description: Nocturnal ventilation through a nasal mask to avoid sleep apneas
Study NCT01177150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-28431754/ Placebo
Description: Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses, the evening dose will be administered at 10 hours after the morning dose.
Study NCT01177150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-28431754
Description: Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
Study NCT02963077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250
Study NCT02963077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRC (A3384)
Study NCT02963077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRC (A3384)
Study NCT02963077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Questran
Study NCT02963077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Questran
Study NCT02963077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02963077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00837564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management
Study NCT03694535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bladder wall thermotherapy with Mitomycin-c
Description: application of intravesical mitomycin-C with hyperthermia
Study NCT03911635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: URAGPI technique
Description: the Urethral Advancement, Glanuloplasty and Preputioplasty
Study NCT00838838 — intervention group
Intervention type: DRUG
Intervention: Testosterone Undeconate (Nebido-R, BAY86-5037)
Description: Male patients > 18yrs in medical practices fulfilling all criteria for documentation.
Study NCT03791307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Pilates group
Description: The participants will perform only exercises based on the traditional Pilates method, 2 times a week, for 50 minutes, for 16 weeks.
Study NCT03791307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Pilates group
Description: The participants will perform exercises based on the Pilates method alternated with active rest periods on treadmill ergometer, 2 times a week, for 50 minutes, for 16 weeks.
Study NCT01923740 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE V EECSS
Description: Subjects receiving XIENCE V
Study NCT01923740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorb BVS System
Description: Subjects receiving Absorb BVS System
Study NCT01572857 — intervention group
Intervention type: BIOLOGICAL
Intervention: urinary excretion of FLC immunoglobulin
Description: First phase :~Collection of four urine samples daily for 2 days:~* Of the 24-hour urine~* at 8 AM~* at 12 AM~* at 4 PM~On each of these urine samples, the following analysis will be performed:~* Proteinuria~* Albuminuria~* Urinary FLC (Freelite ™)~* Urine creatinine~Second phase:~Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row.
Study NCT01370863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD557
Description: 0.5 mg tablet t.i.d. for 4 weeks on top of stable PPI treatment
Study NCT01370863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo tablet t.i.d. for 4 weeks on top of stable PPI treatment
Study NCT01330446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
Study NCT01330446 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 by mouth every morning for a 28 day cycle.
Study NCT01330446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Series of questionnaires completed at different time points before, during, and at study completion.
Study NCT01330446 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Series of questionnaires completed at different time points before, during, and at study completion.
Study NCT03531268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PGx Testing
Description: Pharmacogenomic (PGx) testing will be administered to all subjects. The results of PGx testing will be evaluated for clinical utility. Subjects will be evaluated based on whether PGx testing has clinical utility or has no clinical utility.
Study NCT03946566 — intervention group
Intervention type: PROCEDURE
Intervention: Acupuncture
Description: Using acupuncture, electric acupuncture, moxibustion and acupoint injection treatment.
Study NCT01343719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 661051
Description: medium dose solution for oral administration
Study NCT01343719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 661051
Description: low dose solution for oral administration
Study NCT01343719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 661051
Description: high dose solution for oral administration
Study NCT01343719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 661051
Description: low dose tablet
Study NCT01343719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution for administration
Study NCT01343719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 661051
Description: medium dose tablet
Study NCT02558699 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physician's personal experience
Description: physician's personal experience
Study NCT02558699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual rotor mapping
Description: Virtual rotor mapping
Study NCT01893593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Guideline summary and data feedback from a baseline medical record review and a multifaceted intervention to improve clinical systems
Study NCT01893593 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Guideline summary and data feedback from a baseline medical record review
Study NCT00919711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actonel®
Description: Oral Actonel® (Risedronate) in total a 150mg per month (one 75mg tablet to be taken on each of 2 consecutive days per month).
Study NCT04075604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified Dose on Specified Days
Study NCT04075604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Specified Dose on Specified Days
Study NCT03913728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug level blood tests
Description: All information included previously.
Study NCT03913728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Interview
Description: All information included previously.
Study NCT03404869 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ORL-1M - D-mannose
Description: Oral ORL-1M
Study NCT03289546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: The mindfulness training protocol will include the following basic components of traditional mindfulness-based stress reduction training: 1) training in awareness of sensations (body scan); 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life, and in recognizing when the attention is no longer focused on a specific object of attention; and 4) training in 'open awareness'.
Study NCT03289546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Exercise sessions will be led by CPR- and exercise-certified YMCA instructors and supervised by the senior research assistant. Sessions will consist of 10 minutes of warm-up, 40 minutes of aerobic exercise (walking on a treadmill), 10 minutes of cool down and stretching. Participants will receive heart monitors at the beginning of the study and will be trained by the senior research assistant to exercise targeting heart rates at 65-75% of the age predicted max heart rate or at an intensity of 12-13 in the Borg scale of the rate of perceived exertion.
Study NCT02447679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomine
Description: thalidomine (400mg/day) for 1 year to prevent HCC recurrence
Study NCT02447679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur-uracil
Description: tegafur-uracil (2 tablelet twice a day) for 1 year to prevent HCC recurrence
Study NCT04075604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Specified Dose on Specified Days
Study NCT04075604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Specified Dose on Specified Days
Study NCT02887560 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transoesophageal echocardiography
Study NCT03375814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crocin
Description: This group (osteoarthritic patients) can receive crocin with conventional therapy
Study NCT03375814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The group that takes Placebo Oral Tablet. They received the conventional treatment and Placebo Pills..
Study NCT00962663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICA-105665
Description: Subjects randomized to receive ICA -105665 will receive 200 mg BID
Study NCT00962663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.
Study NCT00962663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to receive placebo will receive placebo to ICA~-105665 at all scheduled dosing times on Days 1 to 4 and placebo to Ibuprofen on the morning of Day 4.
Study NCT00743743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Longevinex brand resveratrol supplement
Description: 1 capsule daily for 52 weeks containing 215 mg of resveratrol active ingredient
Study NCT00743743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 capsule of placebo daily for 52 weeks
Study NCT01843452 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RADIOTHERAPY
Description: External beam radiotherapy (daily fraction dose 1.8Gy) on Monday through Friday starting on study day 1.~* Days 1-28, dose of 36 Gy in 1.8 Gy/fraction (20 fractions) to the clinical target volume 1 (CTV1) including the primary tumor and involved lymph nodes and areas at risk for metastatic spread (which includes gross tumour volumes (GTV) and a 1-cm expansion, mesorectal space, inguinal, femoral, external iliac, internal iliac, and common iliac vessels).~* Days 29-45, a boost dose of 23.4 Gy in 1.8 Gy/fraction (13 fractions) to the GTV.
Study NCT01843452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PANITUMUMAB
Description: 6 mg/kg IV administered over 60 min infusion on days 1,15 and 29.
Study NCT01843452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MITOMYCIN
Description: 10 mg/m2 IV administered over 15 min infusion on days 1 and 29.
Study NCT01843452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPECITABINE
Description: 825mg/m2 orally twice daily on study days 1 through 45.
Study NCT03389893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab, an interleukin (IL)-4 receptor alpha (IL-4Rα) antagonist, is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. (FDA approved on March 28, 2017.)
Study NCT03389893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dupilumab
Description: Dupilumab, an interleukin (IL)-4 receptor alpha (IL-4Rα) antagonist, is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. (FDA approved on March 28, 2017.)
Study NCT03389893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.
Study NCT03389893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.
Study NCT03728192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mangosteen extract
Description: For Mangosteen group :DNA fragmentation assay is used to identify apoptosis.1×106 cells were harvested and treated with mangosteen pericarp extract for 48 h For Camptothecin group : Cells were also treated with standard anticancer drug Camptothecin to act as a positive control.
Study NCT01703533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2566
Description: Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
Study NCT01703533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Strawberry flavored solution and Water for Injection
Study NCT01160991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glucose clamp technique
Description: euglycemic hyperinsulinemic clamp with target blood glucose of 90 mg/dl (5 mmol/l), followed by hyperglycemic clamp, target blood glucose of 180 mg/dl (10 mmol/l) for measurement of insulin sensitivity and insulin secretion
Study NCT01160991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glucose clamp technique
Description: euglycemic hyperinsulinemic clamp with target blood glucose of 90 mg/dl (5 mmol/l), followed by hyperglycemic clamp, target blood glucose of 180 mg/dl (10 mmol/l) for measurement of insulin sensitivity and insulin secretion
Study NCT01160991 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Glucose clamp technique
Description: euglycemic hyperinsulinemic clamp with target blood glucose of 90 mg/dl (5 mmol/l), followed by hyperglycemic clamp, target blood glucose of 180 mg/dl (10 mmol/l) for measurement of insulin sensitivity and insulin secretion
Study NCT01160991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.
Study NCT01160991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.
Study NCT01160991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are given at 8:00 a.m.
Study NCT04374929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: StealthTrac Temporary Pacing Lead Plus Negative Pressure Wound Therapy
Description: Following fixation of the StealthTrac Lead, Negative Pressure Wound Therapy is applied over the incision site.
Study NCT04374929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: StealthTrac Temporary Pacing Lead Plus Anti-Inflammatory Glucocorticoid
Description: • Methylprednisolone 125 mg administered over 30 minutes beginning at least 30 minutes prior to the incision and StealthTrac Lead insertion procedure. This intravenous dose can be repeated every 8 hours on day one of the insertion from 1-3 doses depending on the patient's ability to take oral medications. It can be administered daily thereafter until the patient is able to take oral dosing. In normal circumstances, post op day 2, commence oral glucocorticoid (see below for recommended oral dosing).~Oral (PO) glucocorticoid preparations and dosing:~* Prednisone 40-60 mg orally daily based on BMI category. BMI categories: Low (\<18); Medium (18-30); High (>30). Low and medium are assigned 40 mg daily. High BMI is assigned 60 mg daily dose. This while the StealthTrac lead remains in place.~* Methylprednisolone 16-32 mg daily based on BMI (low, medium and high) while the StealthTrac Lead remains in place.
Study NCT04374929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Two StealthTrac Temporary Pacing Leads (Increased Electrode Spacing)
Description: Once the first StealthTrac Lead is placed using the procedure described in the AtaCor Temporary Pacing System Instructions for Use (DOC-10085), load a second StealthTrac Lead into the same MACH I Delivery Tool, unless it was damaged during insertion of the first StealthTrac Lead, in which case a new MACH I Delivery Tool should be used.~Insert the second StealthTrac Lead through (1) a different intercostal muscle path within the same intercostal space or (2) within an adjacent intercostal space. Increased electrode spacing is achieved by pacing between the leads.
Study NCT04374929 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: StealthTrac Lead Only (Control)
Description: A single StealthTrac Lead is placed with no additional treatment.
Study NCT02239653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician communication
Study NCT04075604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Specified Dose on Specified Days
Study NCT01253460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/m2 by vein (IV) over 30 minutes, 2 hours following the dose of Sapacitabine on days 1, 2, and 3 of each 28 day course.
Study NCT01253460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein over 6 - 8 hours on day 3 of course 1 after cyclophosphamide, then at 500 mg/m2 on day 1, after cyclophosphamide for subsequent courses. Each course is 28 days.
Study NCT01253460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine
Description: 350 mg flat dose by mouth in the morning of days 1,2, and 3 of each 28 day course.
Study NCT06257004 — intervention group
Intervention type: GENETIC
Intervention: Saliva collection (screening of all participants)
Description: All participants will give a salive sample (self-sampling kit) - selection of 25% extremes (UMC and AMC) participants for WGS and linkage analysis
Study NCT06257004 — intervention group
Intervention type: GENETIC
Intervention: Bloodsampling
Description: Based on the results of the WGS, a selection will be made of the 5% most extremes (UMC and AMC) participants for the iPSC-VSMC generation
Study NCT00919711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60 mg, once every 6 months, Subcutaneous
Study NCT03790163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Drug: levobupivacaine at room temperature ( 23˚C) and second group levobupivacaine warmed to the (30˚C) while the third group levobupivacaine warmed to the body temperature (37˚C)
Study NCT03790163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine
Description: Drug: levobupivacaine at room temperature ( 23˚C) and second group levobupivacaine warmed to the (30˚C) while the third group levobupivacaine warmed to the body temperature (37˚C)
Study NCT02306733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergometrine
Description: 100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv).